Assessment of infection risks prior to lung transplantation

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 578-583

  Luong, Me Linh ^a,b   Morrissey, Orla ^c   Husain, Shahid ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Aspergillus; Burkholderia; infection; lung transplantation; Pseudomonas

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CHLORHEXIDINE; COTRIMOXAZOLE; ISONIAZID; ITRACONAZOLE; PSEUDOMONIC ACID;

ANTIBIOTIC PROPHYLAXIS; ASPERGILLUS; ATYPICAL MYCOBACTERIOSIS; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS; BURKHOLDERIA; BURKHOLDERIA CENOCEPACIA; BURKHOLDERIA CEPACIA INFECTION; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TREATMENT FAILURE; FUNGAL COLONIZATION; GOLD STANDARD; GRAFT RECIPIENT; GRAFT SURVIVAL; HISTOPLASMOSIS; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INFECTION RISK; INVASIVE ASPERGILLOSIS; LATENT TUBERCULOSIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM ABSCESSUS; NONHUMAN; PNEUMONIA; POSTPRIMARY TUBERCULOSIS; PSEUDALLESCHERIASIS; PSEUDOMONAS; PSEUDOMONAS INFECTION; PSEUDOMONAS PNEUMONIA; REINFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RISK ASSESSMENT; SCEDOSPORIUM; SEROLOGY; SINUSITIS; STAPHYLOCOCCUS INFECTION; TOXOPLASMOSIS; TRACHEOBRONCHITIS; TREATMENT CONTRAINDICATION; TUBERCULIN TEST;

BACTERIAL INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LUNG TRANSPLANTATION; MYCOSES; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE PERIOD; RECURRENCE; RESPIRATORY SYSTEM; RISK ASSESSMENT;

EID: 78349308920     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833f9f93     Document Type: Review

References (37)

1. Cystic Fibrosis Foundation. Patient registry 2008. Bethesda, MD: Cystic Fibrosis Foundation; 2008 Contract No.: Document Numberj.
2. Mattner F, Fischer S, Weissbrodt H, et al. Postoperative nosocomial infections after lung and heart transplantation. J Heart Lung Transplant 2007; 26:241-249.
3. Aguilar-Guisado M, Givalda J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007; 7:1989-1996.
4. Zeglen S, Wojarski J, Wozniak-Grygiel E, et al. Frequency of Pseudomonas aeruginosa colonizations/infections in lung transplant recipients. Transplant Proc 2009; 41:3222-3224.
5. Bonvillain RW, Valentine VG, Lombard G, et al. Postoperative infections in cystic fibrosis and noncystic fibrosis patients after lung transplantation. J Heart Lung Transplant 2007; 26:890-897.
6. Holzmann D, Speich R, Kaufmann T, et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation 2004; 77:134-136.
7. Leung MK, Rachakonda L, Weill D, et al. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol 2008; 22:192-196.
8. HadjiliadisD,Steele MP, ChaparroC, et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26:834-838.
9. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with Gramnegative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009; 103:743-749.
10. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85:771-774.
11. Vos R, Vanaudenaerde BM, Geudens N, et al. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 2008; 31:1037-1045.
12. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163:43-48.
13. Meachery G, De Soyza A, Nicholson A, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008; 63:725-731.
14. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025-1030.
15. Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63:732-737.
16. Murray S, Charbeneau J, Marshall BC, et al. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:363-371.
17. Liou TG, Adler FR, Cox DR, et al. Lung transplantation and survival in children with cystic fibrosis. N Engl J Med 2007; 357:2143-2152.
18. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 2010; 362:9-17.
19. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299-323.
20. Fowler SJ, French J, Screaton NJ, et al. Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics. Eur Respir J 2006; 28:1204-1210.
21. Chalermskulrat W, Sood N, Neuringer IP, et al. Nontuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006; 61:507-513.
22. Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447-1455.
23. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111.
24. Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis 2010; 12:220-229.
25. Helmi M, Love RB, Welter D, et al. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123:800-808.
26. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112:1160-1164.
27. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6:3008-3016.
28. Liu M, Worley S, Mallory GB Jr, et al. Fungal infections in pediatric lung transplant recipients: colonization and invasive disease. J Heart Lung Transplant 2009; 28:1226-1230.
29. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9:1903-1911.
30. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S180-S191.
31. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89-99.
32. Sahi H, Avery RK, Minai OA, et al. Scedosporium apiospermum (Pseudal-lescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant 2007; 26:350-356.
33. Fischer SA, Avery RK. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009; 9 (Suppl 4):S7-18.
34. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276-1284.
35. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48:1657-1665.
36. Cuellar-Rodriguez J, Avery RK, Lard M, et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009; 49:710-716.
37. Gourishankar S, Doucette K, Fenton J, et al. The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation 2008; 85:980-985.